Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (14)

2019

  1. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

    Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1

2016

  1. High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer

    Oncologist, Vol. 21, Núm. 2, pp. 150-155

2015

  1. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study

    Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795

2014

  1. Consenso sobre la biopsia selectiva del ganglio centinela en el cáncer de mama. Revisión 2013 de la Sociedad Española de Senología y Patología Mamaria

    Revista Espanola de Patologia

  2. Consensus on sentinel lymph node biopsy in breast cancer. Review of the Spanish Society of Senology and Breast Pathology 2013

    Revista de Senologia y Patologia Mamaria, Vol. 27, Núm. 1, pp. 43-53

2013

  1. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

2010

  1. Adjuvant docetaxel for high-risk, node-negative breast cancer

    New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210

  2. Current controversies in the management of breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286

  3. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial

    Breast Cancer Research and Treatment, Vol. 119, Núm. 1, pp. 145-153

2008

  1. Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer

    Cancer Treatment Reviews, Vol. 34, Núm. 8, pp. 701-709

2004

  1. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

    Annals of Oncology, Vol. 15, Núm. 9, pp. 1358-1365

  2. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain

    Annals of Oncology, Vol. 15, Núm. 2, pp. 201-206

2000

  1. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer

    Clinical Cancer Research, Vol. 6, Núm. 6, pp. 2356-2362

  2. Doxorubicin and paclitaxel in advanced breast carcinoma: Importance of prior adjuvant anthracycline therapy

    Cancer, Vol. 89, Núm. 11, pp. 2169-2175